NLRP3 and cardiovascular disorder: Colchicine, a recognized NLRP3 inhibitor traditionally used for gout, has shown the potential to reduce cardiovascular risks in clinical trials, emphasizing NLRP3’s significant role in cardiovascular disease progression and mitigation (Martinez et al., 2015; Nidorf et al., 2020).